Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · IEX Real-Time Price · USD
40.17
+0.68 (1.72%)
At close: Mar 27, 2024, 4:00 PM
39.48
-0.69 (-1.72%)
After-hours: Mar 27, 2024, 5:44 PM EDT

Kymera Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Net Income
-146.96-154.81-100.22-54.64-41.25-21.47
Depreciation & Amortization
3.572.982.41.760.830.21
Share-Based Compensation
43.1235.4824.975.191.20.65
Other Operating Activities
-2.55-36.73-56.1126.7757.132.75
Operating Cash Flow
-102.83-153.09-128.9588.1317.91-17.86
Operating Cash Flow Growth
---392.21%--
Capital Expenditures
-34.48-2.84-1.6-9.1-0.53-1.36
Change in Investments
174.3723.36-98.24-413.49-15.950
Investing Cash Flow
139.8920.52-99.84-422.59-16.49-1.36
Share Issuance / Repurchase
4.27154.13251.13196.840.070
Debt Issued / Paid
-0.08-1.13-0.85-0.55-0.37-0.3
Other Financing Activities
---92.9835.2153.23
Financing Cash Flow
4.19153250.28289.2634.9152.93
Net Cash Flow
41.2520.4321.5-45.236.3333.71
Free Cash Flow
-137.31-155.92-130.5479.0317.37-19.22
Free Cash Flow Growth
---354.92%--
Free Cash Flow Margin
-174.71%-332.98%-179.24%232.22%592.13%-
Free Cash Flow Per Share
-2.35-2.89-2.724.5510.23-10.25
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).